Ying Huang has served as Chief Executive Officer of Legend Biotech since November 2020, after joining the company as Chief Financial Officer in July 2019. He leads all aspects of Legend’s global operations, including research, development, clinical programs, manufacturing, regulatory affairs, commercial activities, and business development. Huang played a central role in guiding Legend through its crossover financing and one of the largest biotech IPOs of 2020, and he continues to drive strategic collaborations and pipeline advancement for cutting‑edge cell therapies in oncology.
Before Legend Biotech, Huang was Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch, leading a team covering more than 30 biotechnology companies across major therapeutic areas and consistently ranking as a top biotechnology analyst. He began his career as a Principal Scientist at Schering‑Plough, focusing on small molecule drug discovery, and is co‑author of multiple patents and peer‑reviewed publications.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations
